Non-clear  ||| S:0 E:10 ||| JJ
cell  ||| S:10 E:15 ||| NN
advanced  ||| S:15 E:24 ||| VBD
kidney  ||| S:24 E:31 ||| NN
cancer ||| S:31 E:37 ||| NN
:  ||| S:37 E:39 ||| :
is  ||| S:39 E:42 ||| VBZ
there  ||| S:42 E:48 ||| RB
a  ||| S:48 E:50 ||| DT
gold  ||| S:50 E:55 ||| NN
standard ||| S:55 E:63 ||| NN
?  ||| S:63 E:65 ||| .
Renal  ||| S:65 E:71 ||| JJ
cell  ||| S:71 E:76 ||| NN
carcinoma  ||| S:76 E:86 ||| NNS
( ||| S:86 E:87 ||| -LRB-
RCC ||| S:87 E:90 ||| NNP
)  ||| S:90 E:92 ||| -RRB-
accounts  ||| S:92 E:101 ||| NNS
for  ||| S:101 E:105 ||| IN
approximately  ||| S:105 E:119 ||| RB
3 ||| S:119 E:120 ||| CD
%  ||| S:120 E:122 ||| NN
of  ||| S:122 E:125 ||| IN
all  ||| S:125 E:129 ||| DT
new  ||| S:129 E:133 ||| JJ
cancer  ||| S:133 E:140 ||| NN
diagnosis  ||| S:140 E:150 ||| VBD
every  ||| S:150 E:156 ||| DT
year ||| S:156 E:160 ||| NN
.  ||| S:160 E:162 ||| .
RCC  ||| S:162 E:166 ||| NNP
arises  ||| S:166 E:173 ||| VBZ
from  ||| S:173 E:178 ||| IN
the  ||| S:178 E:182 ||| DT
renal  ||| S:182 E:188 ||| JJ
epithelium  ||| S:188 E:199 ||| NN
and  ||| S:199 E:203 ||| CC
represents  ||| S:203 E:214 ||| VBZ
85 ||| S:214 E:216 ||| CD
%  ||| S:216 E:218 ||| NN
of  ||| S:218 E:221 ||| IN
all  ||| S:221 E:225 ||| DT
kidney  ||| S:225 E:232 ||| NN
tumors ||| S:232 E:238 ||| NNS
.  ||| S:238 E:240 ||| .
According  ||| S:240 E:250 ||| VBG
to  ||| S:250 E:253 ||| TO
histology ||| S:253 E:262 ||| VB
,  ||| S:262 E:264 ||| ,
these  ||| S:264 E:270 ||| DT
neoplasms  ||| S:270 E:280 ||| NNS
are  ||| S:280 E:284 ||| VBP
divided  ||| S:284 E:292 ||| VBN
into  ||| S:292 E:297 ||| IN
the  ||| S:297 E:301 ||| DT
following  ||| S:301 E:311 ||| JJ
types ||| S:311 E:316 ||| NNS
:  ||| S:316 E:318 ||| :
clear  ||| S:318 E:324 ||| JJ
cell ||| S:324 E:328 ||| NN
,  ||| S:328 E:330 ||| ,
papillary ||| S:330 E:339 ||| NN
,  ||| S:339 E:341 ||| ,
chromophobe ||| S:341 E:352 ||| NN
,  ||| S:352 E:354 ||| ,
oncocytoma ||| S:354 E:364 ||| NN
,  ||| S:364 E:366 ||| ,
collecting  ||| S:366 E:377 ||| VBG
duct ||| S:377 E:381 ||| NN
,  ||| S:381 E:383 ||| ,
and  ||| S:383 E:387 ||| CC
unclassified ||| S:387 E:399 ||| JJ
.  ||| S:399 E:401 ||| .
Approximately ||| S:401 E:414 ||| RB
,  ||| S:414 E:416 ||| ,
75 ||| S:416 E:418 ||| CD
%  ||| S:418 E:420 ||| NN
of  ||| S:420 E:423 ||| IN
RCCs  ||| S:423 E:428 ||| NNS
are  ||| S:428 E:432 ||| VBP
of  ||| S:432 E:435 ||| IN
the  ||| S:435 E:439 ||| DT
clear  ||| S:439 E:445 ||| JJ
cell  ||| S:445 E:450 ||| NN
type  ||| S:450 E:455 ||| NN
and  ||| S:455 E:459 ||| CC
in  ||| S:459 E:462 ||| IN
recent  ||| S:462 E:469 ||| JJ
years ||| S:469 E:474 ||| NNS
,  ||| S:474 E:476 ||| ,
there  ||| S:476 E:482 ||| EX
have  ||| S:482 E:487 ||| VBP
been  ||| S:487 E:492 ||| VBN
substantial  ||| S:492 E:504 ||| JJ
advances  ||| S:504 E:513 ||| NNS
in  ||| S:513 E:516 ||| IN
the  ||| S:516 E:520 ||| DT
understanding  ||| S:520 E:534 ||| NN
of  ||| S:534 E:537 ||| IN
its  ||| S:537 E:541 ||| PRP$
molecular  ||| S:541 E:551 ||| JJ
biology  ||| S:551 E:559 ||| NN
leading  ||| S:559 E:567 ||| VBG
to  ||| S:567 E:570 ||| TO
the  ||| S:570 E:574 ||| DT
development  ||| S:574 E:586 ||| NN
of  ||| S:586 E:589 ||| IN
effective  ||| S:589 E:599 ||| JJ
treatments ||| S:599 E:609 ||| NNS
.  ||| S:609 E:611 ||| .
However ||| S:611 E:618 ||| RB
,  ||| S:618 E:620 ||| ,
there  ||| S:620 E:626 ||| EX
is  ||| S:626 E:629 ||| VBZ
still  ||| S:629 E:635 ||| RB
an  ||| S:635 E:638 ||| DT
area  ||| S:638 E:643 ||| NN
of  ||| S:643 E:646 ||| IN
uncertainty  ||| S:646 E:658 ||| NN
with  ||| S:658 E:663 ||| IN
regard  ||| S:663 E:670 ||| NN
to  ||| S:670 E:673 ||| TO
non-clear  ||| S:673 E:683 ||| JJ
cell  ||| S:683 E:688 ||| NN
histologies ||| S:688 E:699 ||| NN
.  ||| S:699 E:701 ||| .
Scarce  ||| S:701 E:708 ||| JJ
studies  ||| S:708 E:716 ||| NNS
have  ||| S:716 E:721 ||| VBP
been  ||| S:721 E:726 ||| VBN
conducted  ||| S:726 E:736 ||| VBN
testing  ||| S:736 E:744 ||| VBG
different  ||| S:744 E:754 ||| JJ
drugs  ||| S:754 E:760 ||| NNS
in  ||| S:760 E:763 ||| IN
this  ||| S:763 E:768 ||| DT
patient  ||| S:768 E:776 ||| JJ
population ||| S:776 E:786 ||| NN
.  ||| S:786 E:788 ||| .
Thus ||| S:788 E:792 ||| RB
,  ||| S:792 E:794 ||| ,
most  ||| S:794 E:799 ||| JJS
of  ||| S:799 E:802 ||| IN
the  ||| S:802 E:806 ||| DT
evidence  ||| S:806 E:815 ||| NN
comes  ||| S:815 E:821 ||| VBZ
from  ||| S:821 E:826 ||| IN
small  ||| S:826 E:832 ||| JJ
phase  ||| S:832 E:838 ||| NN
II  ||| S:838 E:841 ||| NNP
trials ||| S:841 E:847 ||| NNS
,  ||| S:847 E:849 ||| ,
retrospective  ||| S:849 E:863 ||| JJ
analysis ||| S:863 E:871 ||| NN
,  ||| S:871 E:873 ||| ,
or  ||| S:873 E:876 ||| CC
expanded  ||| S:876 E:885 ||| JJ
access  ||| S:885 E:892 ||| NN
programs ||| S:892 E:900 ||| NNS
.  ||| S:900 E:902 ||| .
Recent  ||| S:902 E:909 ||| JJ
insights  ||| S:909 E:918 ||| NNS
in  ||| S:918 E:921 ||| IN
the  ||| S:921 E:925 ||| DT
molecular  ||| S:925 E:935 ||| JJ
basis  ||| S:935 E:941 ||| NN
of  ||| S:941 E:944 ||| IN
these  ||| S:944 E:950 ||| DT
tumors  ||| S:950 E:957 ||| NNS
have  ||| S:957 E:962 ||| VBP
opened  ||| S:962 E:969 ||| VBN
a  ||| S:969 E:971 ||| DT
promising  ||| S:971 E:981 ||| JJ
research  ||| S:981 E:990 ||| NN
field ||| S:990 E:995 ||| NN
.  ||| S:995 E:997 ||| .
Molecules  ||| S:997 E:1007 ||| NNS
targeting  ||| S:1007 E:1017 ||| VBG
mammalian  ||| S:1017 E:1027 ||| JJ
target  ||| S:1027 E:1034 ||| NN
of  ||| S:1034 E:1037 ||| IN
rapamycin ||| S:1037 E:1046 ||| NN
,  ||| S:1046 E:1048 ||| ,
epidermal  ||| S:1048 E:1058 ||| JJ
growth  ||| S:1058 E:1065 ||| NN
factor  ||| S:1065 E:1072 ||| NN
receptor ||| S:1072 E:1080 ||| NN
,  ||| S:1080 E:1082 ||| ,
c-MET ||| S:1082 E:1087 ||| NNP
,  ||| S:1087 E:1089 ||| ,
vascular  ||| S:1089 E:1098 ||| JJ
endothelial  ||| S:1098 E:1110 ||| JJ
growth  ||| S:1110 E:1117 ||| NN
factor ||| S:1117 E:1123 ||| NN
,  ||| S:1123 E:1125 ||| ,
and  ||| S:1125 E:1129 ||| CC
platelet-derived  ||| S:1129 E:1146 ||| JJ
growth  ||| S:1146 E:1153 ||| NN
factor  ||| S:1153 E:1160 ||| NN
are  ||| S:1160 E:1164 ||| VBP
among  ||| S:1164 E:1170 ||| IN
some  ||| S:1170 E:1175 ||| DT
of  ||| S:1175 E:1178 ||| IN
the  ||| S:1178 E:1182 ||| DT
promising  ||| S:1182 E:1192 ||| JJ
drugs  ||| S:1192 E:1198 ||| NNS
tested  ||| S:1198 E:1205 ||| VBN
in  ||| S:1205 E:1208 ||| IN
this  ||| S:1208 E:1213 ||| DT
setting ||| S:1213 E:1220 ||| NN
.  ||| S:1220 E:1222 ||| .
This  ||| S:1222 E:1227 ||| DT
article  ||| S:1227 E:1235 ||| NN
reviews  ||| S:1235 E:1243 ||| VBZ
the  ||| S:1243 E:1247 ||| DT
mechanisms  ||| S:1247 E:1258 ||| NNS
of  ||| S:1258 E:1261 ||| IN
disease  ||| S:1261 E:1269 ||| NN
on  ||| S:1269 E:1272 ||| IN
RCC  ||| S:1272 E:1276 ||| NNP
and  ||| S:1276 E:1280 ||| CC
summarizes  ||| S:1280 E:1291 ||| JJ
treatment  ||| S:1291 E:1301 ||| NN
options  ||| S:1301 E:1309 ||| NNS
with  ||| S:1309 E:1314 ||| IN
a  ||| S:1314 E:1316 ||| DT
particular  ||| S:1316 E:1327 ||| JJ
focus  ||| S:1327 E:1333 ||| NN
on  ||| S:1333 E:1336 ||| IN
patients  ||| S:1336 E:1345 ||| NNS
with  ||| S:1345 E:1350 ||| IN
non-clear  ||| S:1350 E:1360 ||| JJ
cell  ||| S:1360 E:1365 ||| NN
tumors ||| S:1365 E:1371 ||| NNS
.  ||| S:1371 E:1373 ||| .
